NCT06452329View on ClinicalTrials.gov

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

260

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

April 28, 2025

Study Completion Date

July 31, 2025

Conditions
Gastric CancerGastroesophageal Junction Cancer
Interventions
DRUG

Nivolumab

As prescribed by treating physician

Trial Locations (2)

430030

Local Institution - 0001, Wuhan

Unknown

Tianjin Happy Life Technology Co., Ltd, Shanghai

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY